학술논문

INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)
Document Type
Journal
Source
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA; SEP 2023, 23 pS390-pS390, 1p. Supplement: 1
Subject
Language
English
ISSN
21522669